In 2017 and in the first half of 2018 in the group of companies “Probiotic” was organized by “turnkey” and conducted 63 pre-clinical studies, which is 15% higher than the previous two years.
Lead preparations 5 therapeutic areas – neurology, cardiology, infectious diseases (besides HIV, HCV, TB), gastroenterology and anesthesia.
In the structure consistently high rate of generics, which account for nearly 60% of all studies. The share of original drugs account for 19%, third and fourth place is shared, i.e. biosimilars, and new combinations of generic pharmaceutical.
We will remind, preclinical studies of group of companies “Probiotic” holds in own vivarium with a total area of 230 sq. m., in strict accordance with GLP regulations.
Source: GK “Probiotic”